-+ 0.00%
-+ 0.00%
-+ 0.00%

ProMIS Neurosciences Completes Enrollment for Phase 1b Trial of PMN310 in Alzheimer’s Disease

Reuters·12/18/2025 12:30:24

Please log in to view news